Canaccord Genuity Rates Twist Bioscience (TWST) buy

Canaccord Genuity has reaffirmed its positive stance on Twist Bioscience Corporation, setting a $90.00 target for the shares, a 2.79% upside from the current price.

By EarningsIQ Research Desk · Published Jun 15, 2026, 12:01 PM EDT · Updated Jun 22, 2026, 8:01 AM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

Canaccord Genuity rated Twist Bioscience Corporation ($TWST) "buy" with a $90 price target on June 15, 2026.

Since the rating, $TWST is up 5.4% after 1 week, up 14.6% after 1 month and up 64.3% to date (from the $80.79 close on Jun 15, 2026).

TWST Twist Bioscience Corporation

$132.75 +309.85% year to date

Daily close · Oct 16, 2026

Key Points

Canaccord Genuity analyst Kyle Mikson reiterated a buy rating on Twist Bioscience Corporation, NasdaqGS:TWST, with a $90.00 price target on June 15, 2026.
Canaccord Genuity's $90 price target implies 2.79% upside from Twist Bioscience Corporation's ($TWST) current $87.56 share price.
The stock changed hands recently at $87.56, moving within a 52-week band from $23.30 to $170.23.
Wall Street sentiment includes a consensus buy view from 12 analysts, featuring an overall mean price target of $109.58.

Get $TWST trade alerts by text

We text you when insiders, Congress or big funds trade $TWST. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Twist Bioscience Corporation alert may contain errors. Disclosures

Canaccord Genuity Updates View on Twist Bioscience

Canaccord Genuity has reaffirmed its bullish stance on Twist Bioscience Corporation, NasdaqGS:TWST, with analyst Kyle Mikson maintaining a buy rating and a $90.00 price target on June 15, 2026. This update keeps the focus on the biotechnology firm as it navigates shifting market expectations and develops synthetic DNA products for diverse research and diagnostic fields.

Stock Price Context and Market Range

The shares traded recently at $87.56 on Monday, reflecting a notable journey from the company's 52-week low of $23.30 up to a high of $170.23. The stock sits above its 200-day moving average of $70.35, though it trades below its 50-day moving average of $119.81. With a market capitalization near $11.0 billion and a high beta of 2.22, the equity experiences wider price swings than the broader market.

12-month forecast

$TWST price target

Twist Bioscience Corporation daily closes and this analyst's $90 target. Not advice.

Analysts Set New Price Targets

Wall Street coverage features a range of opinions from major financial institutions. On October 13, 2026, TD Cowen maintained a buy rating on the stock, lifting its target to $190.00 from $115.00. Earlier, on October 12, 2026, Canaccord Genuity itself maintained a buy rating while raising its target to $205.00 from $120.00. Jefferies initiated coverage on October 8, 2026, with a hold rating and a $150.00 price target. Barclays kept an overweight rating on October 7, 2026, setting a $215.00 target, while Guggenheim maintained a buy rating on October 1, 2026, moving its target to $212.00. Leerink Partners maintained an outperform rating on September 29, 2026, with a $190.00 target after previously keeping an outperform rating with a $160.00 target on September 17, 2026. On the cautious side, BWS Financial maintained a sell rating with a $45.00 target on September 18, 2026. Altogether, 12 analyst opinions shape a consensus buy recommendation alongside a mean target price of $109.58, with individual targets stretching from a low of $36.00 to a high of $160.00.

Inside Twist Bioscience Operations

Headquartered in South San Francisco, California and led by CEO Dr. Emily Marine Leproust Ph.D., Twist Bioscience manufactures and sells synthetic DNA-based products for use in therapeutics, diagnostics, agriculture, and academic research. The firm creates synthetic genes, oligo pools, immunoglobulin G proteins, and next-generation sequencing tools that help labs speed up discovery and testing workflows.

What to Watch Next for Twist Bioscience

Market participants will look toward the company's next earnings report scheduled for November 16, 2026, for further clues on revenue progress and profitability. Because analyst targets and ratings shift over time based on incoming financial data, investors typically track subsequent filings and management commentary to measure operational execution against broader industry trends.